<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132116</url>
  </required_header>
  <id_info>
    <org_study_id>15 7834 08</org_study_id>
    <nct_id>NCT03132116</nct_id>
  </id_info>
  <brief_title>Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis</brief_title>
  <acronym>BIGG</acronym>
  <official_title>Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare effect of intra-nodal injection of gentamicin versus placebo on the outcome at 28
      days of suppurated cat scratch disease's (CSD) lymphadenitis treated by oral azithromycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind controlled study versus placebo. Patients with suppurated CSD's lymphadenitis
      will receive immediately after the pus aspiration (performed for a diagnostic purpose) an
      intra-nodal injection of gentamicin or of placebo (NaCl 0,9%) and be treated with oral
      azithromycin for 5 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency at day 28 of CSD's adenitis favorable outcome</measure>
    <time_frame>Day 28</time_frame>
    <description>Adenitis favorable outcome characterized as : Reduction of the volume of the adenitis, Without requirement of supplementary needle aspirations after day 7's visit, And without requirement of a surgical excision or incision of the adenitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of the adenitis</measure>
    <time_frame>from Day 0 to Day 28</time_frame>
    <description>Percentage of volume reduction of the adenitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pain related to the adenitis</measure>
    <time_frame>between Day 0, Day 7 and Day 28</time_frame>
    <description>Percentage of reduction of the pain related to the adenitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fistulization of the adenitis</measure>
    <time_frame>Day 7 and day 28</time_frame>
    <description>Number of patients with persisting cutaneous fistulization of the adenitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical action</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of patients requiring surgical excision or incision of the adenitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein C reactive</measure>
    <time_frame>Day 0 and day 7</time_frame>
    <description>Percentage of decrease of serum Protein C reactive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic resistance</measure>
    <time_frame>Day 28</time_frame>
    <description>Genotypic profile of resistance to macrolides and aminoglycosides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>Day 7 and day 28</time_frame>
    <description>Incidence of Treatment-Emergent Events linked to the study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cat-Scratch Disease</condition>
  <arm_group>
    <arm_group_label>Gentamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-nodal injection of gentamicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intra-nodal injection of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gentamicin</intervention_name>
    <description>After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).</description>
    <arm_group_label>Gentamicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Suppurated CSD's adenitis:

               -  Suppurated form of adenitis confirmed by echography

               -  Serology positive for Immunoglobulin G and/or Immunoglobulin M against B.
                  henselae

        Exclusion Criteria:

          -  Suppurated adenitis non related to CSD

          -  Non-suppurated CSD's adenitis

          -  Suppurated CSD's adenitis already fistulized

          -  Suspected visceral B. henselae infection (neurologic or ophthalmic symptoms,
             hepato-splenic or valvular involvement confirmed by echography)

          -  Immunodepression (except diabetes)

          -  Pregnancy

          -  Contraindication to pus aspiration from lymphadenitis (history of bleeding or patient
             taking curative anticoagulation therapy or platelet count &lt; 50.000/mm3)

          -  Contraindication to azithromycin (history of QT interval prolongation, history of
             liver toxicity of hypersensitivity to macrolides or treatment with ergotamine,
             dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to
             aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume MARTIN-BLONDEL, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Toulouse, Hospital Pierre-Paul Riquet, Infectious &amp; Tropical Diseases department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume MARTIN-BLONDEL, MD, PhD</last_name>
    <phone>+33 (0) 5 61 77 96 99</phone>
    <email>martin-blondel.g@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexa DEBARD, MD</last_name>
    <phone>+33 (0) 5 61 77 95 86</phone>
    <email>debard.a@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Albi Hospital</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Anne LAFFONT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auch Hospital</name>
      <address>
        <city>Auch</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ARISTA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel DUPON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michel DUPON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice BONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cahors Hospital</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane SIRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castres Hospital</name>
      <address>
        <city>Castres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence-Sarah KHATIBI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre WEINBRECK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence ADER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montauban Hospital</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc DELAVAISSIERE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MORQUIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nîmes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine LECHICHE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pau Hospital</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie GABORIEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perpignan Hospital</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa COLOMBAIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodez Hospital</name>
      <address>
        <city>Rodez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno GUERIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tarbes Hospital</name>
      <address>
        <city>Tarbes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian BUSATO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Microbiology Laboratory</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume MARTIN-BLONDEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume MARTIN-BLONDEL, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat Scratch Disease's lymphadenitis</keyword>
  <keyword>Infectious Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphadenitis</mesh_term>
    <mesh_term>Cat-Scratch Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

